Illumina Announces Favorable Outcome of Its Patent Litigation Against Life Technologies

Illumina ILMN announced today that District Court Judge Cathy Ann Bencivengo of the U.S. District Court for the Southern District of California granted Illumina's motion for summary judgment that its sequencing systems do not infringe U.S. Patent Nos. 5,616,478; 5,958,698 and 6,001,568, being asserted by Life Technologies Corporation in a lawsuit filed against Illumina in 2009. The Court ruled that, “Life Tech cannot establish, as a matter of law, that the accused Illumina systems infringe” the patents. Jay Flatley, Illumina's President and CEO, stated, “We are obviously very pleased with the favorable outcome of this suit. Since Life Technologies filed this patent infringement suit against Illumina in 2009, we have consistently believed and strongly argued that our sequencing technology does not infringe any of the patents Life Technologies asserted against us in this case. The federal court's ruling has now vindicated our position. While our policy is to respect the valid and enforceable intellectual property rights of others, and take licenses where appropriate, this case demonstrates we are determined to defend vigorously any unfounded claims of infringement.” About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. Forward-Looking Statements This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.